Direct targeting of myostatin by anti-myostatin antibodies was found to prevent the loss of muscle mass and function in mice bearing LLC tumors [158], whereas enhanced expression of follistatin by inhibitors of histone deacetylases, such as valproic acid or trichostatin-A, failed to improve cachexia in tumor-bearing rodents [166]. The gene discussed is MSTN; the disease is neoplasm.